On February 12, 2020 4SC AG (4SC, FSE Prime Standard: VSC) reported that it will attend and present at the World Congress of Cutaneous Lymphomas in Barcelona, Spain, from the 12-14 Feb 2020 (Press release, 4SC, FEB 12, 2020, View Source [SID1234554222]). A summary of the key presentations, abstracts and posters is listed below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation – HDAC inhibitor resminostat counteracts disease-related gene expression and cytokine secretion in CTCL cells
Poster presentation – Resminostat increases NK cell-mediated lysis of malignant cells beneficially affecting the function of opsonizing antibodies
Poster – RESMAIN Study Update – A multicentre, double blind, randomised, placebo controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy.